Why iHeartMedia (IHRT) Shares Are Sliding Today

iHeartMedia (NASDAQ: IHRT) shares fell 24.4% after mixed Q2 results. The company reported a GAAP loss of $0.52 per share, worse than the $0.33 consensus, while revenue rose 4.7% to $977.2 million, slightly above expectations. EBITDA guidance for next quarter missed estimates, weighing on profitability outlook.

Original reporting
Published Aug 11, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why iHeartMedia (IHRT) Shares Are Sliding Today — source image
Decision brief

The 30-second read

$IHRTBearishMed
01

Why it matters

Traders may reprice IHRT on guidance credibility and near-term cash-flow expectations rather than top-line growth, increasing sensitivity to subsequent quarters.

02

Market read

A large single-day drop tied to earnings and guidance provides a fresh catalyst for positioning and volatility management.

03

What to watch

The piece emphasizes EBITDA guidance shortfall but provides no detail on cost actions, one-time items, or the magnitude of the guidance miss, which could affect how persistent the repricing is.

Relevance 8/10Novelty 7/10Timing: after-hours/afternoon session reaction to Q2 results

Background

The article frames the move as a profitability disappointment: EPS missed and next-quarter EBITDA guidance fell short, despite a small revenue beat.

Company-level read

Ticker impact

$IHRTBearishHigh confidence
Context

iHeartMedia shares fell 24.4% after Q2 results missed EPS expectations and EBITDA guidance for next quarter fell short.

Expected impact

Bearish near-term bias, with elevated volatility likely to persist after the guidance shortfall.

Evidence & confidence

The article cites a GAAP EPS loss worse than consensus and explicitly flags next-quarter EBITDA guidance below analyst estimates, which typically drives immediate repricing.

Market effects

Weak profitability guidance from a large radio/media operator can pressure sentiment across leveraged media and advertising-exposed cash-flow stories.

No specific regional spillover described.

No explicit global linkage beyond broad media/entertainment demand commentary.

Counterpoint

Despite the selloff, the article notes revenue narrowly beat expectations and Digital Audio Group/podcasting demand grew, which could limit long-term damage if margins stabilize.

Key entities

  • iHeartMedia

    NASDAQ-listed media company whose Q2 EPS and next-quarter EBITDA guidance drove a sharp selloff.

Related articles

$IHRTMed

A Steep Dip For iHeart Shares After Shaky Q2 Review

iHeartMedia (IHRT) shares fell sharply after the company’s late Q2 release showed a net loss despite revenue rising by more than $43.5 million, according to the earnings report. On Tuesday, IHRT closed down over 20% on heavy volume. The article cites $5.04 billion total debt and ~8.9% weighted average interest rate.

$IHRTMed

In iHeartMedia's Q2, Digital Drives Gains

iHeartMedia reported Q2 revenue of $977M, up 4.7% year over year, and $82.5M net loss. Digital Audio Group revenue rose 12% to $364M, with podcast revenue up 21% to $162M, while Multiplatform Group revenue fell about 2% to $536M. iHeart expects $125M annualized cost savings in 2026 and mid-single-digit Q3 2026 revenue growth.

$IHRTMed

iHeart Extends Debt Again As Multiplatform Losses Persist In Q2

iHeartMedia reported Q2 revenue of $977 million, up 4.7%, driven by Digital Audio Group revenue of $364 million (+12.4%) and podcast revenue of $162 million (+20.7%). Operating income was $35.5 million, net loss $82.4 million. The company extended its $450 million ABL facility maturity to Jan 2029 and still has about $4.7 billion net debt.

$XLOMed

Xilio Therapeutics, Inc. (XLO): Results of Operations and Financial Condition

Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancin